| 1.27 0.08 (6.72%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.84 |
1-year : | 2.15 |
| Resists | First : | 1.58 |
Second : | 1.84 |
| Pivot price | 1.15 |
|||
| Supports | First : | 1.15 |
Second : | 0.88 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.1 |
| MA(100) : | 0.89 |
MA(250) : | 0.81  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.1 |
D(3) : | 69.4 |
| RSI | RSI(14): 59.1 |
|||
| 52-week | High : | 1.58 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CMMB ] has closed below upper band by 20.9%. Bollinger Bands are 45.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.34 - 1.35 | 1.35 - 1.35 |
| Low: | 1.23 - 1.23 | 1.23 - 1.24 |
| Close: | 1.26 - 1.27 | 1.27 - 1.28 |
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Fri, 26 Jul 2024
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Fri, 26 Jul 2024
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement - StockTitan
Thu, 25 Jul 2024
Chemomab stock gains on trial win (update) (NASDAQ:CMMB) - Seeking Alpha
Thu, 25 Jul 2024
Chemomab Therapeutics Reveals Data From Mid-Stage Study For Liver Disease Candidate, Stock Plunges On Capital Raise - Benzinga
Thu, 25 Jul 2024
Chemomab Therapeutics Announces $10 Million Private Placement - Quantisnow
Thu, 25 Jul 2024
Chemomab Therapeutics Announces $10 Million Private Placement - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 188 (M) |
| Held by Insiders | 14.9 (%) |
| Held by Institutions | 23.8 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 62 (K) |
| EPS | -1.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.3 % |
| Return on Equity (ttm) | -93.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.83 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|